Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex F Herrera

Showing results (61-70 of 175) with videos related to

Pageof 18
Sort By:
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaLaurie H Sehn, Alex F Herrera, Christopher R Flowers, et al.
Haematologica|January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphomaJoo Y Song, Mary Nwangwu, Ting-Fang He, et al.
British Journal of Haematology|May 26, 2024
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphomaTamer Othman, John H Baird, Stacy Pak, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Haematologica|September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapySantiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Pageof 18

Showing results (61-70 of 175) with videos related to

Sort By:
Pageof 18
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation StudyAlex F Herrera, Manish R Patel, John M Burke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaLaurie H Sehn, Alex F Herrera, Christopher R Flowers, et al.
Haematologica|January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphomaJoo Y Song, Mary Nwangwu, Ting-Fang He, et al.
British Journal of Haematology|May 26, 2024
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphomaTamer Othman, John H Baird, Stacy Pak, et al.
Blood Cancer Journal|June 25, 2026
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotinShin Yeu Ong, Lu Chen, Jomel Meeko Manzano, et al.
Haematologica|September 5, 2024
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapySantiago Mercadal, Kwang Woo Ahn, Mariam Allbee-Johnson, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
Pageof 18